Dengue vaccines: Challenges, development, current status and prospects

Indian Journal of Medical Microbiology

Volumn 33, Issue 1, 2015, Pages 3-15

  Ghosh, A ^a   Dar, L ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Challenges; Dengue vaccine; Prospect India; Status

Indexed keywords

DENGUE VACCINE; DNA VACCINE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VIRUS VACCINE; VIRUS VECTOR; YELLOW FEVER VACCINE;

ANTIBODY RESPONSE; ANTIVIRAL THERAPY; CELL CULTURE; CELLULAR IMMUNITY; COST EFFECTIVENESS ANALYSIS; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; HOSPITALIZATION; HUMAN; IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOPATHOLOGY; MORBIDITY; MUTAGENESIS; NONHUMAN; PUBLIC HEALTH; REVIEW; SECONDARY INFECTION; SEROCONVERSION; VACCINATION; VIRUS ATTENUATION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL (TOPIC); DENGUE VIRUS; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG SCREENING; IMMUNOLOGY; INDIA; ISOLATION AND PURIFICATION; TRENDS;

CLINICAL TRIALS AS TOPIC; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DRUG APPROVAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; INDIA;

EID: 84920895551     PISSN: 02550857     EISSN: 19983646     Source Type: Journal    
DOI: 10.4103/0255-0857.148369     Document Type: Review

References (110)

1. World Health Organization, Geneva, 2013. Dengue and severe dengue [factsheet no. 117, revised September 2013]. Available from: http://www.who.int/mediacentre/factsheets/fs117/en/[Last accessed on 2013 Dec 5].
2. Centers for Disease Control and Prevention, Atlanta. Dengue. Available from: http://www.cdc.gov/dengue/[Last accessed on 2013 Dec 5].
3. Kyle JL, Harris E. Global spread and persistence of dengue. Annu Rev Microbiol 2008;62:71-92.
4. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine 2011;29:7221-8.
5. World Health Organization, Geneva, 2009. Dengue: Guidelines for diagnosis, treatment, prevention and control. Available from: http://whqlibdoc.who.int/publications/2009/978924154 7871- eng.pdf [Last accessed on 2013 Dec 5].
6. Lam SK. Denguev2V-new global initiative supporting transition from vaccine to vaccination. Vaccine 2010;28:2060-1.
7. Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg 2011;84:200-7.
8. Halstead SB. Dengue. Lancet 2007;370:1644-52.
9. World Health Organization, Geneva, 2012. Global Strategy for dengue prevention and control, 2012-2020: WHO report. Available from: http://www.who.int/denguecontrol/9789241504034/en/[Last accessed on 2013 Dec 10].
10. st century. Trends Microbiol 2002;10:100-3.
11. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: Disease regulation by immune complexes. Lancet Infect Dis 2010;10:712-22.
12. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. I V. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 1970;42:311-28.
13. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: Implications for vaccine development. Cell Host Microbe 2008;4:229-38.
14. Thullier P, Lafaye P, Megret F, Deubel V, Jouan A, Mazie JC. A recombinant Fab neutralizes dengue virus in vitro. J Biotechnol 1999;69:183-90.
15. Rodenhuis-Zybert IA, Wilschut J, Smit JM. Dengue virus life cycle: Viral and host factors modulating infectivity. Cell Mol Life Sci 2009;67:2773-86.
16. Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 2010;7:128-39.
17. Murgue B, Roche C, Chungue E, Deparis X. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J Med Virol 2000;60:432-8.
18. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Ann Rev Immunol 2011;29:587-619.
19. Thomas SJ. The necessity and quandaries of dengue vaccine development. J Infect Dis 2011;203:299-303.
20. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccine 2009;5:33-40.
21. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006;24:1238-41.
22. Swaminathan S, Khanna N. Dengue vaccine-current progress and challenges. Curr Sci 2010;98:369-78.
23. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: Role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002;66:264-72.
24. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001;19:3179-88.
25. Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J Virol 1999;73:783-6.
26. An J, Kimura-Kuroda J, Hirabayashi Y, Yasui K. Development of a novel mouse model for dengue virus infection. Virology 1999; 263: 70-7.
27. Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, Ma SH, et al. Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol 1998;72:9729-37.
28. Chen L, Ewing D, Subramanian H, Block K, Rayner J, Alterson KD, et al. A het-erologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. J Virol 2007;81:11634-9.
29. Guirakhoo F, Pugachv K, Arroyo J, Miller C, Zhang ZX, Weltzin R, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Genetic reconstructions, dose adjustment and antibody responses against wild-type dengue virus isolates. Virology 2002;298:146-59.
30. Raviprakash K, Ewing D, Simmons M, Porter KR, Jones TR, Hayes CG, et al. Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 2003;315:345-52.
31. Perng GC, Lei HY, Lin YS, Chokephaibulkit K. Dengue vaccines: Challenge and confrontation. World J Vaccin 2011;1:109-30.
32. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis 2011;24:442-50.
33. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952;1:30-50.
34. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004;189:990-1000.
35. Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, et al. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J Infect Dis 2006;193:1658-65.
36. Moi ML, Lim CK, Chua KB, Takasaki T, Kurane I. Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells. PLoS Negl Trop Dis 2012;6:e1536.
37. Jin X, Block OT, Rose R, Schlesinger J. Dengue vaccine development and dengue viral neutralization and enhancement assays. Antivir Ther 2009;14:739-49.
38. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. Am J Trop Med Hyg 2009;81:825-33.
39. World Health Organization, Geneva, 2008. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. Available from: http://whqlibdoc.who.int/hq/2008/WHO- IVB-08.12-eng.pdf [Last accessed on 2013 Dec 12].
40. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007;5:518-28.
41. Raviprakash K, Defang G, Burgess T, Porter K. Advances in dengue vaccine development. Hum Vaccin 2009;8:520-8.
42. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: Effect of yellow fever preimmunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006;2:60-7.
43. th ed. Philadelphia: Saunders Press; 2013. p. 1042-51.
44. Bhamarapravati N, Yoksan S. Live attenuated tetravalent dengue vaccine. Vaccine 2000;18S: 44-7.
45. Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): Clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 1987;65:189-95.
46. Vaughn DW, Hoke CH Jr, Yoksan S, LaChance R, Innis BL, Rice RM, et al. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 1996;14:329-36.
47. Bhamarapravati N, Yoksan S. Study of bivalent dengue vaccine in volunteers. Lancet 1989;1:1077.
48. Sanchez V, Gimenez S, Tomlinson B, Chan PK, Thomas GN, Forrat R, et al. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 2006;24:4914-26.
49. Balas C, Kennel A, Deauvieau F, Sodoyer R, Arnaud-Barbe N, Lang J, et al. Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains. J Infect Dis 2011;203:103-8.
50. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003;69:24-31.
51. Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: Selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 2003;69 Suppl 6:17-23.
52. Edelman R, Wasserman SS, Bodison SA, Putnak JR, Eckels KH, Tang D, et al. Phase 1 trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003;69 Suppl 6:48-60.
53. Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008;78:426-33.
54. Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis B, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg 2011;85:341-51.
55. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 2013;88:73-88.
56. Puri B, Nelson WM, Henchal EA, Hoke CH, Eckels KH, Dubois DR, et al. Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells. J Gen Virol 1997;78:2287-91.
57. Whitehead SS, Falgout B, Hanley KA, Blaney Jr JE Jr, Markoff L, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol 2003;77:1653-7.
58. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996;70:3930-7.
59. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 2001;65:405-13.
60. Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, Durbin AP, et al. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg 2001;65:414-9.
61. Whitehead SS, Hanley KA, Blaney JE Jr, Gilmore LE, Elkins WR, Murphy BR. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 2003;21:4307-16.
62. Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: Construction and biological properties. J Virol 1999;73:3095-101.
63. Bray M, Lai CJ. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Natl Acad Sci USA 1991;88:10342-6.
64. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000;74:5477-85.
65. Guy B, Saville M, Lang J. Development of SanofiPasteur tetravalent dengue vaccine. Hum Vaccin 2010;6.
66. Guy B, Barrere B, Malinowski C, Saville M, Tessou R, Lang J. From research to phase III: Preclinical, industrial and clinical development of the SanofiPasteur tetravalent dengue vaccine. Vaccine 2011;29:7229-41.
67. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004;78:4761-75.
68. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, et al. Evaluation of interferences between dengue vaccine 33. serotypes in a monkey model. Am J Trop Med Hyg 2009;80:302-11.
69. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006;2:60-7.
70. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010;201:370-7.
71. Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines. Vaccine 2011;29:3863-72.
72. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010;201:370-7.
73. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 2012;38:1559-67.
74. Vu TT, Holmes EC, Duong V, Nguyen TQ, Tran TH, Quail M, et al. Emergence of the Asian 1 genotype of dengue virus serotype 2 in Vietnam: In vivo fitness advantage and lineage replacement in south-east Asia. PLoS Negl Trop Dis 2010;4:e757.
75. Mahalingam S, Herring BL, Halstead SB. Call to action for dengue vaccine failure. Emerg Infect Dis 2013;19:1335-7.
76. Villar LÁ, Rivera-Medina DM, Arredondo-García JL, Boaz M, Starr-Spires L, Thakur M, et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: A randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J 2013;32:1102-9.
77. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011;29:7251-60.
78. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 2003;7:11436-47.
79. Osorio JE, Brewoo J, Silengo SJ, Arguello J, Moldovan IR, Tary-Lehmann M, et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in cynomolgus macaques. Am J Trop Med Hyg 2011;84:978-87.
80. World Health Organization, Geneva, 2013. Dengue vaccine candidates in clinical development. Available from: http://www.who.int/immunization/sage/meetings/2013/april/1- Dengue-SAGE-Apr2013- Vaccine-Candidates.pdf [Last accessed on 2013 Dec 10].
81. Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 2004;71:811-21.
82. Blaney JE Jr, Sathe NS, Goddard L, Hanson CT, Romero TA, Hanley KA, et al. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4. Vaccine 2008;26:817-28.
83. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011;29:7242-50.
84. Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial. J Infect Dis 2013;207:957-65.
85. Putnak R, Barvir DA, Burrous JM, Dubois DR, D'Andrea VM, Hoke CH, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996;174:1176-84.
86. Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005;23:4442-52.
87. Simmons M, Burgess T, Lynch J, Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010;396:280-8.
88. Kelly EP, Greene JJ, King AD, Innis BL. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 2000;18:2549-59.
89. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, et al. Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010;28:2705-15.
90. Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, Elkins R, et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 2000;18:3113-22.
91. Guzman MG, Rodriguez R, Hermida L, Alvarez M, Lazo L, Muné M, et al. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg 2003;69:129-34.
92. Chiang CY, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, et al. A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One 2011;6:e23319.
93. Kochel T, Wu SJ, Raviprakash K, Hobart P, Hoffman S, Porter K, et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997;15:547-52.
94. Raviprakash K, Kochel TJ, Ewing D, Simmons M, Phillips I, Hayes CG, et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000;18:2426-34.
95. Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Ewing D, et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 2006;353:166-73.
96. Apt D, Raviprakash K, Brinkman A, Semyonov A, Yang S, Skinner C, et al. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 2006;24:335-44.
97. Porter KR, Kochel TJ, Wu SJ, Raviprakash K, Phillips I, Hayes CG. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Arch Virol 1998;143:997-1003.
98. Lu H, Xu XF, Gao N, Fan DY, Wang J, An J. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: Their immunity and protective efficacy in mice. Mol Immunol 2013;54:109-14.
99. Danko JR, Beckett CG, Porter KR. Development of dengue DNA vaccines. Vaccine 2011;29:7261-6.
100. Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008;82:6927-34.
101. White LJ, Parsons MM, Whitmore AC, Williams BM, de Silva A, Johnston RE. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J Virol 2007;81:10329-39.
102. Brandler S, Lucas-Hourani M, Moris A, Frenkiel MP, Combredet C, Février M, et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 2007;1:e96.
103. Holman DH, Wang D, Raviprakash K, Raja NU, Luo M, Zhang J, et al. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin Vaccine Immunol 2007;14:182-9.
104. Raja NU, Holman DH, Wang D, Raviprakash K, Juompan LY, Deitz SB, et al. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector. Am J Trop Med Hyg 2007;76:743-51.
105. National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, India, 2013. Dengue cases and deaths in the country since 2007 Available from: http://nvbdcp.gov.in/den-cd.html. [Last accessed on 2013 Dec 20].
106. the%20People%20on%20Health.pdf [Last accessed on 2013 Dec 20].
107. Douglas DL, DeRoeck DA, Mahoney RT, Wichmann O. Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders. Plos Negl Trop Dis 2013;7:e7127.
108. Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T, et al. Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies. Plos One 2013;8:e64595.
109. Normille D. Surprising new dengue virus throws a spanner in disease control efforts. Science 2013;342:415.
110. Edelman R. Dengue vaccines approach the finish line. Clin Infect Dis 2007;45:S56-60.